Meeting
2021 ASCO Annual Meeting
Outcomes of first, second, and third-generation anaplastic lymphoma kinase (ALK) inhibitors in non-small cell lung cancer brain metastases (NSCLCBM).
Authors
Vineeth Tatineni
Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH
Vineeth Tatineni , Patrick Joseph O'Shea , Yasmeen Rauf , Xuefei Jia , Erin Sennett Murphy , Samuel T. Chao , John H. Suh , David M. Peereboom , Manmeet Singh Ahluwalia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Brain Metastases
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2034)
DOI
10.1200/JCO.2021.39.15_suppl.2034
Abstract #
2034
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
First Author: Renaud Descourt
Poster
2018 ASCO Annual Meeting
Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety.
First Author: Benjamin Besse
Poster
2021 ASCO Annual Meeting
Circulating tumor DNA to investigate resistance mechanism and clone evolution of ALK TKI treated lung adenocarcinoma.
First Author: Gang Hua
Poster
2020 ASCO Virtual Scientific Program
Longitudinal monitoring by next generation sequencing of plasma cell-free DNA in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with ALK tyrosine kinase inhibitors.
First Author: Minsuk Kwon